-transparent.png){kind=logo}
The neuropharmacological and neurochemical features of Progressive Supranuclear Palsy (PSP) are reviewed, together with the results obtained by various therapeutic trials. PSP is a neurodegenerative disease which often causes Parkinsonian symptoms but dopaminomimetic drugs have given rise to poor improvement, in spite of dopamine decrease observed in PSP patients' nigrostriatal region. The uselessness of L-DOPA therapy in PSP patients may explain the numerous failures encountered in PSP patients misdiagnosed as Parkinsonian. On the basis of the recent discovery of striatal dopaminergic receptor abnormalities and of interaction between various neurotransmitters, the authors suggest some possible therapeutic substances that might improve the outcome of the disease.
G Finali, and
G L Piccinin, and
M Piccirilli, and
E Stefano
September 1989,
Annals of neurology,
G Finali, and
G L Piccinin, and
M Piccirilli, and
E Stefano
July 1991,
Neurology,
G Finali, and
G L Piccinin, and
M Piccirilli, and
E Stefano
September 1982,
Archives of neurology,
G Finali, and
G L Piccinin, and
M Piccirilli, and
E Stefano
January 1971,
Archiv fur Psychiatrie und Nervenkrankheiten,
G Finali, and
G L Piccinin, and
M Piccirilli, and
E Stefano
January 2003,
Ryoikibetsu shokogun shirizu,
G Finali, and
G L Piccinin, and
M Piccirilli, and
E Stefano
October 2003,
Hospital medicine (London, England : 1998),
G Finali, and
G L Piccinin, and
M Piccirilli, and
E Stefano
December 1995,
Rinsho shinkeigaku = Clinical neurology,
G Finali, and
G L Piccinin, and
M Piccirilli, and
E Stefano
May 2003,
Revue neurologique,
G Finali, and
G L Piccinin, and
M Piccirilli, and
E Stefano
January 2013,
Nursing standard (Royal College of Nursing (Great Britain) : 1987),
G Finali, and
G L Piccinin, and
M Piccirilli, and
E Stefano
March 1986,
The Journal of the Association of Physicians of India,
